How Quickly Does Gvoke Start Working?
Gvoke (glucagon injection) reverses severe hypoglycemia symptoms in as little as 10 minutes for most patients. Clinical data shows blood glucose rising above 70 mg/dL within 10 minutes in 99% of cases, with full recovery typically by 15-30 minutes.[1][2]
What Happens in Clinical Studies?
In trials for Gvoke HypoPen and prefilled syringe, 100 mg/mL doses given to adults with insulin-induced hypoglycemia raised blood glucose:
- ≥70 mg/dL by 10 minutes in 99% of patients.
- ≥70 mg/dL sustained for 150 minutes in 100% of patients.
Similar results held for pediatric patients aged 2+, with onset as fast as 9 minutes in some cases.[1][3]
Time to Symptom Relief
Patients often report feeling better within 5-10 minutes, as glucagon prompts the liver to release stored glucose. Full alertness returns by 15 minutes for most, though severe cases may take up to 30 minutes.[2][4]
Factors Affecting Speed
- Dose and delivery: 1 mg adult dose via auto-injector or syringe acts fastest; nasal glucagon (e.g., Baqsimi) is comparable but slightly slower at 10-15 minutes.
- Patient factors: Faster in those with adequate glycogen stores; delays possible in malnourished patients or prolonged hypoglycemia.
- Administration: Subcutaneous injection in thigh or abdomen; incorrect site or technique slows onset.[2][5]
Gvoke vs. Other Glucagon Options
| Option | Onset Time | Delivery | Notes |
|--------|------------|----------|-------|
| Gvoke (injection) | 10 min | Auto-injector/syringe | Shelf-stable, no reconstitution needed. |
| Baqsimi (nasal) | 10-15 min | Nasal spray | No needles; works in unconscious patients. |
| Traditional glucagon kits | 10-20 min | IM injection after mixing | Less user-friendly for emergencies. |
Gvoke edges out older kits due to ready-to-use format.[2][6]
When to Use and Risks if Delayed
Administer immediately if blood sugar <54 mg/dL or patient is unconscious/symptomatic. Untreated severe hypoglycemia risks seizures or coma within minutes. Gvoke has low nausea risk (4%) vs. IV glucose.[1][4]
Sources
[1]: Gvoke Prescribing Information (FDA)
[2]: Gvoke Clinical Pharmacology
[3]: Pediatric Trial Data (NEJM)
[4]: ADA Hypoglycemia Guidelines
[5]: Endocrine Society Review
[6]: DrugPatentWatch: Glucagon Patents